دورية أكاديمية
Role of dofetilide in patients with ventricular arrhythmias.
| العنوان: | Role of dofetilide in patients with ventricular arrhythmias. |
|---|---|
| المؤلفون: | Shantha G; Cardiac Electrophysiology, Wake Forest University, 1, Medical Center Blvd, Winston-Salem, NC, 27157, USA. gpalaman@wakehealth.edu., Singleton M; WellSpan Hospital, York, PA, USA., Kozak P; Cardiac Electrophysiology, Wake Forest University, 1, Medical Center Blvd, Winston-Salem, NC, 27157, USA., Bodziock G; Cardiac Electrophysiology, Wake Forest University, 1, Medical Center Blvd, Winston-Salem, NC, 27157, USA., Atreya AR; Cardiac Electrophysiology, University of Arkansas, Little Rock, USA., Narasimhan B; Debakey Cardiovascular Center, Houston Methodist Hospital, Houston, TX, USA., Deshmukh A; Cardiac Electrophysiology, Mayo Clinic, Rochester, MN, USA., Liang JJ; Cardiac Electrophysiology, University of Michigan, Ann Arbor, MI, USA., Hranitzky P; University of North Carolina, Chapel Hill, NC, USA., Whalen P; Cardiac Electrophysiology, Wake Forest University, 1, Medical Center Blvd, Winston-Salem, NC, 27157, USA., Bhave P; Cardiac Electrophysiology, Wake Forest University, 1, Medical Center Blvd, Winston-Salem, NC, 27157, USA. |
| المصدر: | Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing [J Interv Card Electrophysiol] 2024 Jan; Vol. 67 (1), pp. 91-97. Date of Electronic Publication: 2023 May 29. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Springer Country of Publication: Netherlands NLM ID: 9708966 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1572-8595 (Electronic) Linking ISSN: 1383875X NLM ISO Abbreviation: J Interv Card Electrophysiol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Amsterdam : Springer Original Publication: Norwell, MA : Kluwer Academic Publishers, c1997- |
| مواضيع طبية MeSH: | Tachycardia, Ventricular*/complications , Ventricular Premature Complexes* , Cardiomyopathies*/complications, Humans ; Phenethylamines/therapeutic use |
| مستخلص: | Background or Purpose: To assess effectiveness of dofetilide in reducing the burden of ventricular arrhythmias (VAs). Background: Prior small sample studies show that dofetilide has benefit in reducing VA. However, large sample investigations with long-term follow-up are lacking. Methods: Two hundred seventeen consecutive patients admitted between January 2015 and December 2021 for dofetilide initiation for control of VA were assessed. Dofetilide was successfully started in 176 patients (81%) and had to be discontinued in the remaining 41 patients (19%). Dofetilide was initiated for control of ventricular tachycardia (VT) in 136 patients (77%), whereas 40 (23%) patients were initiated on dofetilide for reducing the burden of premature ventricular complexes (PVCs). Results: The mean follow-up was 24 ± 7 months. In total, among the 136 VT patients, 33 (24%) died, 11 (8%) received a left ventricular assist device (LVAD), and 3 (2%) received a heart transplant during follow-up. Dofetilide was discontinued in 117 (86%) patients due to lack of sustained effectiveness during follow-up. Dofetilide use was associated with similar odds of the composite outcome of all-cause mortality/LVAD/heart transplant (OR: 0.97, 0.55-4.23) in patients with ischemic cardiomyopathy (ICM) compared to those with non-ischemic cardiomyopathy (NICM). Dofetilide did not reduce PVC burden during follow-up in the 40 patients with PVCs (mean baseline PVC burden: 15%, at 1-year follow-up: 14%). Conclusions: Dofetilide use was less effective in reducing VA burden in our cohort of patients. Randomized controlled studies are needed to confirm our findings. (© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.) |
| References: | Shantha G, Alyesh D, Ghanbari H, Oral H. Antiarrhythmic drug therapy and all-cause mortality after catheter ablation of atrial fibrillation: a propensity-matched analysis. Heart Rhythm. 2019;16:1368–73. (PMID: 10.1016/j.hrthm.2019.06.00731201962) Mounsey JP, DiMarco JP. Cardiovascular drugs. Dofetilide. Circulation. 2000;102:2665–70. (PMID: 10.1161/01.CIR.102.21.266511085972) Boriani G, Lubinski A, Capucci A, et al. A multicentre, double-blind randomized crossover comparative study on the efficacy and safety of dofetilide vs sotalol in patients with inducible sustained ventricular tachycardia and ischaemic heart disease. Eur Heart J. 2001;22:2180–91. (PMID: 10.1053/euhj.2001.267911913480) Bashir Y, Thomsen PE, Kingma JH, et al. Electrophysiologic profile and efficacy of intravenous dofetilide (UK-68,798), a new class III antiarrhythmic drug, in patients with sustained monomorphic ventricular tachycardia Dofetilide Arrhythmia Study Group. Am J Cardiol. 1995;76:1040–4. (PMID: 10.1016/S0002-9149(99)80293-87484858) Baquero GA, Banchs JE, Depalma S, et al. Dofetilide reduces the frequency of ventricular arrhythmias and implantable cardioverter defibrillator therapies. J Cardiovasc Electrophysiol. 2012;23:296–301. (PMID: 10.1111/j.1540-8167.2011.02183.x21955243) http://www.fda.gov/Drugs/DrugSafety/Postmarket DrugSafetyInformationforPatientsandProviders/ucm489271.htm (Accessed on May 07, 2017). http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm489271.htm (Accessed on May 04, 2016). Guanzon AV, Crouch MA. Phase IV trial evaluating the effectiveness and safety of dofetilide. Ann Pharmacother. 2004;38:1142–7. (PMID: 10.1345/aph.1D46515161945) Denetclaw TH, Oshima N, Dowling TC. Dofetilide dose calculation errors in elderly associated with use of the modification of diet in renal disease equation. Ann Pharmacother. 2011;45:e44. (PMID: 10.1345/aph.1Q15921712508) Pokorney SD, Yen DC, Campbell KB. Dofetilide dose reductions and discontinuations in women compared with men. Heart Rhythm. 2018;15:478–84. (PMID: 10.1016/j.hrthm.2018.01.02729605013) Subedi R, Dean RK, Dhamoon AS. Dofetilide-induced severe hepatotoxicity. Am J Ther. 2018;25:e783–4. (PMID: 10.1097/MJT.000000000000079329912716) Fukui S, Katoh H, Tsuzuki NS. Multivariate analysis of risk factors for QT prolongation following subarachnoid hemorrhage. Crit Care. 2003;7:R7–12. (PMID: 10.1186/cc216012793884270671) Makkar RR, Fromm BS, Steinman RT, Meissner MD, Lehmann MH. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA. 1993;27:2590–7. (PMID: 10.1001/jama.1993.03510210076031) Kurokawa J, Tamagawa M, Harada S. Acute effects of oestrogen on the guinea pig and human Ikr channels and drug-induced prolongation of cardiac repolarization. J Physiol. 2008;586:2961–73. (PMID: 10.1113/jphysiol.2007.150367184409942517194) Marill KA, Miller ES. Hypokalemia in women and methadone therapy are the strongest non-cardiologic factors associated with QT prolongation in an emergency department setting. J Electrocardiol. 2017;50:416–23. (PMID: 10.1016/j.jelectrocard.2017.02.001282745425483391) Boriani G, Biffi M, Bacchi L, et al. A randomised cross-over study on the haemodynamic effects of oral dofetilide compared with oral sotalol in patients with ischaemic heart disease and sustained ventricular tachycardia. Eur J Clin Pharmacol. 2002;58:165–9. (PMID: 10.1007/s00228-002-0464-312107600) Boriani G, Biffi M, De Simone N, et al. Repolarization changes in a double-blind crossover study of dofetilide versus sotalol in the treatment of ventricular tachycardia. Pacing Clin Electrophysiol. 2000;23:1935–8. (PMID: 10.1111/j.1540-8159.2000.tb07056.x11139961) Rouet R, Picard S, Libersa C, et al. Electrophysiological effects of dofetilide in an in vitro model of “border zone” between normal and ischemic/reperfused myocardium. Circulation. 2000;101:86–93. (PMID: 10.1161/01.CIR.101.1.8610618309) Ducroq J, Rouet R, Sallé L, et al. Class III effects of dofetilide and arrhythmias are modulated by [K+]o in an in vitro model of simulated-ischemia and reperfusion in guinea-pig ventricular myocardium. Eur J Pharmacol. 2006;532:279–89. (PMID: 10.1016/j.ejphar.2005.12.08316480976) Kassim NA, Althouse AD, Qin D, Leef G, Saba S. Gender differences in management and clinical outcomes of atrial fibrillation patients. J Cardiol. 2017;69:195–200. (PMID: 10.1016/j.jjcc.2016.02.02227262176) Pool PE, Singh SN, Friedrich T. Effects of intravenous dofetilide in patients with frequent premature ventricular contractions: a clinical trial. Clin Cardiol. 2000;23:415–6. (PMID: 10.1002/clc.496023060710875030) |
| فهرسة مساهمة: | Keywords: Dofetilide; Premature ventricular complexes; Ventricular arrhythmia; Ventricular tachycardia |
| المشرفين على المادة: | R4Z9X1N2ND (dofetilide) 0 (Phenethylamines) |
| تواريخ الأحداث: | Date Created: 20230529 Date Completed: 20240108 Latest Revision: 20240108 |
| رمز التحديث: | 20240108 |
| DOI: | 10.1007/s10840-023-01578-w |
| PMID: | 37247098 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 1572-8595 |
|---|---|
| DOI: | 10.1007/s10840-023-01578-w |